Belamcanda (Iris domestica / Belamcanda chinensis): A Comprehensive Reference
1. Identity, Taxonomy, and Botanical Description
1.1 Botanical Name and Taxonomic History
The plant known commercially and in traditional medicine as Belamcanda is formally classified today as Iris domestica, commonly known as the leopard lily, blackberry lily, and leopard flower; it is an ornamental and medicinal plant in the family Iridaceae. Based on molecular DNA sequence evidence, Peter Goldblatt and David Mabberley in Novon 15: 128 (2005) merged the genus Belamcanda into Iris, proposing the new name Iris domestica for what had been called Belamcanda chinensis; this change has been accepted. Despite this reclassification, the name Belamcanda chinensis remains widely used in both the pharmacological literature and official pharmacopeias. Prior to reclassification, Belamcanda chinensis (L.) DC was considered the sole species in the genus Belamcanda Adans., found mainly in Northeast Asia.
In current global taxonomy, Iris domestica (L.) Goldblatt & Mabb. was published in Novon 15: 129 (2005) and belongs to the kingdom Plantae, phylum Tracheophyta, class Liliopsida, order Asparagales, and family Iridaceae. A number of synonyms are recognized in the literature, including Belamcanda punctata Moench, Gemmingia chinensis (L.) Kuntze, Ixia chinensis L., and Pardanthus chinensis Ker Gawl.
1.2 Common Names
- Chinese (TCM): Shegan (å°„å¹²); also Yexuanhua and Jiaojiancao
- English: Blackberry lily, leopard lily, leopard flower
- Pharmacopoeial: Belamcandae Rhizoma (the drug name used in official monographs)
1.3 Botanical Description and Distribution
Belamcanda chinensis (L.) Redouté is a perennial herb belonging to the genus Belamcanda, primarily found in China, but with additional distribution in North Korea, South Korea, Japan, and India. Also referred to as leopard lily and leopard flower, it is a short-lived perennial native to eastern Russia, China, and Japan. The plant is native to Eastern Asia and has been cultivated worldwide in subtropical and temperate climates; owing to the ornamental value of its attractive flowers, it was distributed to Europe as early as the 18th century and to the United States and Caribbean countries in the 19th century.
The plant has flat, sword-like leaves arranged in a fan on a small tuberous rhizome; the foliage grows to 18 inches tall, and the plants produce many offsets. The flowers are followed by clusters of glossy black seeds which resemble blackberry (Rubus) fruit — the characteristic giving rise to the common name "blackberry lily."
1.4 Medicinal Part and Preparation for Use
Belamcandae Rhizoma is the sun-dried rhizome of B. chinensis and has a long history of traditional medicinal use. The rhizomes of B. chinensis are collected in early spring or autumn after cultivation for 2–3 years. The root was washed by immersion in water for 2–3 hours, filleted, and dried. The dried forms are suitable for preparing prescriptions and extracting medicinal components.
2. Pharmacopoeial and Regulatory Status
Belamcanda chinensis is listed in the Pharmacopoeia of the People's Republic of China. The monograph of Belamcandae chinensis rhizoma has also been included in the European Pharmacopoeia. It was adopted as one Chinese medicinal herb in the European Pharmacopoeia (9th edition). There are more than 10 proprietary Chinese medicines already on the market that consist of or originate from B. chinensis.
3. Traditional and Historical Use
3.1 Traditional Chinese Medicine (TCM)
The medicinal history of B. chinensis dates back to the Han Dynasty in China, where it was documented as a treatment for laryngeal paralysis and sore throat. It was first recorded in the Shennong's Herbal Classic (Shennong Bencao Jing), with the effects of clearing heat and detoxifying, eliminating phlegm, and benefiting the pharynx. It has been applied in Chinese medicine for more than 2,000 years.
For thousands of years in China, the rhizome of Belamcanda chinensis has been used to treat inflammation, oxyhepatitis, mumps, acute mastitis, and asthma, as well as throat disorders such as cough, tonsillitis, and pharyngitis. The rhizomes of B. chinensis have been widely used in traditional Chinese medicine as antipyretic agents, antidotes, expectorants, antiphlogistics, and analgesics.
According to the statistics of Zhong Yi Fang Ji Da Ci Dian, there are about 382 ancient formulas containing B. chinensis, most of which are used to treat heat-based diseases, and only 36 ancient formulas are used to treat cold-style diseases. In TCM theory, the rhizome is classified as bitter and cold, targeting the lung and liver meridians. The medicine is bitter and cold and targets the lung and liver meridian; its functions are heat clearance, detoxification, and phlegm elimination, as well as benefiting the pharynx, and it is used to treat heat and poison phlegm, cough and asthma, and sore throat.
Belamcanda chinensis has often been used as the principal medicine in prescriptions for bronchial asthma in both ancient and modern times, such as in "Shegan Mahuang decoction," which is a well-known prescription for the treatment of cold-type asthma in Jīn Guì Yà o Lüè and is known as the "ancestor of prescriptions" by recent generations.
3.2 Use in Other Asian Traditions
The rhizomes of Belamcanda chinensis have been used in Vietnamese and other oriental folk medicine for the treatment of cough, pharyngitis, sore swollen throat, asthma, and phlegm-related conditions. In addition, as a Thai medicinal plant, B. chinensis is used traditionally for the regulation of menstrual disorders. Consequently, B. chinensis is used in pediatrics, gynecology, respiratory issues, carbuncles, gangrene, sores, and poison-related conditions.
The extract of Belamcanda chinensis leaves (BCLE) is a traditional Chinese herbal medicine for the treatment of hyperglycemia in Hainan province, South China. Dried whole herbs of B. chinensis are employed in traditional medicine in Guangdong, Guangxi, and several other areas in China.
4. Phytochemistry: Key Constituents and Active Compounds
More than 200 natural products have been isolated and identified from B. chinensis over the past 40 years. In the past few decades, more than 100 chemical constituents have been isolated, including flavonoids, terpenoids, quinones, organic acids, and other compounds from B. chinensis.
4.1 Isoflavonoids (Principal Class)
Isoflavonoids, flavonoids, and iridal-type triterpenoids are the three main components isolated from the B. chinensis rhizome. Isoflavonoids, including tectorigenin, tectoridin, irigenin, irisflorentin, and iristectorigenin A, are considered the most active compounds of the B. chinensis rhizome.
Tectoridin, iristectorin A, iristectorin B, iridin, tectorigenin, iristectorigenin A, irigenin, irisflorentin, irilone, and dichotomitin were the predominant isoflavonoids in B. chinensis. In the rhizome, tectoridin, followed by its aglycone tectorigenin and iridin, were the most abundant compounds.
Tectorigenin and its glycoside tectoridin are among the most intensively studied compounds. Tectorigenin (TG), an O-methylated isoflavone, is isolated from the rhizome of Belamcanda chinensis (Iridaceae) and represents a traditional Chinese medicine component used for the treatment of inflammatory diseases such as asthma and tonsillitis. Growing evidence suggests that tectorigenin has multiple pharmacological effects, such as anticancer, antidiabetic, hepatoprotective, anti-inflammatory, antioxidative, antimicrobial, cardioprotective, and neuroprotective.
Tectoridin, iridin, tectorigenin, irigenin, and irisflorentin have been identified as the Quality-Markers of Belamcandae Rhizoma — a concept used in Chinese pharmacopoeia quality-control systems to designate the most characteristic and pharmacologically relevant constituents.
4.2 Flavonoids
Flavonoids including irigenin, apigenin, hispidulin, luteolin, isorhamnetin, and rhamnazin; xanthones such as mangiferin, isomangiferin, and neomangiferin; and iridal-type triterpenoids including iriditectoral, iridotectoral A, iridotectoral B, and belamcandal have been isolated from the rhizomes, leaves, and seeds of B. chinensis.
4.3 Iridal-Type Triterpenoids
Many reports have elucidated that isoflavones are major metabolites among the phenolic compounds, and the uniqueness of this plant is to have triterpenoids with an iridal skeleton. These iridal-type triterpenoid compounds exhibit excellent anti-tumor, anti-inflammatory, hepatoprotective, and kidney-protective activity, and they also demonstrate potent ichthyotoxicity against killifish.
Eight new iridal-type triterpenoid derivatives — including two noriridals with ether bridges, two iridals lactone, and four monocyclic iridals — together with five known iridals were identified from the rhizome of Belamcanda chinensis. Their structures were elucidated on the basis of comprehensive spectroscopic methods. Bioassay results showed that belamcanoxide B (1) exhibited moderate cytotoxic activities against HCT-116 and MCF-7 cell lines with IC₅₀ values of 5.58 and 3.35 μM.
4.4 Quinones, Simple Phenols, and Other Constituents
The main group of phytochemicals identified in the dried rhizoma are polyphenols such as isoflavones, xanthone glycosides, stilbenes, simple phenols, and quinones. Another characteristic class of substances are triterpenoid iridals. Quinones (belamcandones A–D), and simple phenols (belallosides A and B) have also been reported in Belamcandae chinensis rhizoma. Polysaccharides represent an additional category. Macromolecular polysaccharides derived from B. chinensis have become a research focus in recent years because of their safety and low toxicity; there are eight polysaccharides isolated from the dried rhizomes of B. chinensis that have undergone structural characterization.
5. Mechanisms of Action
5.1 Anti-inflammatory Pathways
Bioactivity-guided purification of the methylene chloride-soluble fraction of the rhizomes of B. chinensis, based on the inhibition of nitric oxide (NO) production, led to the identification of seventeen known compounds. Their inhibitory effects on NO production in LPS-induced RAW 264.7 macrophage cells were evaluated. Tectorigenin, irigenin, and irisflorentin have been reported to have anti-inflammatory effects. Tectorigenin levels are negatively correlated with interleukin-4 (IL-4) levels in the alveoli and serum; irigenin levels are also negatively correlated with IL-4 levels in the serum; and tectorigenin significantly reduces the content of leukotriene C4 (LTC4).
One report identified that iridal-type triterpenoids are responsible phytochemicals for the anti-inflammatory effects of B. chinensis, expanding the mechanistic understanding beyond isoflavones to include the structurally unique iridal scaffolds.
5.2 Antioxidant Mechanisms
Tectorigenin, a representative isoflavone component in B. chinensis, scavenges DPPH free radicals and inhibits liver damage caused by carbon tetrachloride, thereby exerting antioxidant and hepatoprotective activity.
5.3 Phytoestrogenic / SERM Activity
The isoflavone tectorigenin has been isolated from the rhizome of B. chinensis. Researchers investigated whether this isoflavone has estrogenic and selective estrogen receptor modulator (SERM) activities, and whether they are mediated via estrogen receptor alpha (ERα) or beta (ERβ); binding studies with recombinant human ERα and ERβ showed that tectorigenin binds to both receptor subtypes. In ERα-expressing MCF7 and ERβ-expressing MDA-MB231 reporter gene transfected cells, tectorigenin caused transactivation.
5.4 Anti-Asthmatic Mechanisms
Research has shown that isoflavone compounds have obvious anti-inflammatory, cough-suppressing, expectorant, and anti-asthmatic properties in vivo and effects against bronchial smooth muscle spasm activity.
5.5 Antidiabetic Mechanisms
In preclinical (KK-Ay obese diabetic mice) studies, the F2 component of B. chinensis leaf extract alleviated hyperglycemia and insulin resistance, as indicated by decreased levels of fasting blood glucose, AUC, glycosylated serum protein, LDH, and insulin. High levels of hepatic G6Pase and PEPCK in KK-Ay mice were markedly attenuated by F2. The inhibitory effect of F2 on GSK-3β and the enhancement effect on liver glycogen demonstrated that F2 could significantly inhibit hepatic gluconeogenesis and promote glycogen accumulation. The higher PPARγ showed F2 may prevent insulin resistance via the PI3K signal transduction pathway.
5.6 Neuroprotective Mechanisms
Tectorigenin exerts an increase in the cell viability of PC12 cells damaged by MPP+, demonstrating neuroprotective activity.
5.7 Bone-Related Activity
Tectorigenin promoted the osteogenic differentiation of primary osteoblasts and periodontal ligament cells. Moreover, TG upregulated the expression of the BMP2, BMP4, and Smad-4 genes, and enhanced the expression of Runx2 and Osterix. In vivo studies involving mouse calvarial bone defects with μCT and histological analysis revealed that TG significantly increased new bone formation. Furthermore, TG treatment inhibited osteoclast differentiation and the mRNA levels of osteoclast markers.
6. Scientific Evidence by Area of Use
6.1 Respiratory Disease (Asthma, Bronchitis, Pharyngitis, Cough)
Traditional and Pharmacopoeial Basis: Modern research has shown that Belamcanda chinensis contains isoflavone compounds, dicyclic triterpenoid derivatives, and phenolic compounds with anti-inflammatory properties that affect cough, phlegm, and bronchial asthma, and it is clinically used for the treatment of bronchial asthma, chronic pharyngitis, and cough after infection.
Preclinical Evidence: In an animal study, sixty guinea pigs were randomly divided into a blank control group, model control group, Belamcanda chinensis extract groups (0.8 g/kg, 1.2 g/kg, 1.6 g/kg, respectively), and a dexamethasone acetate tablet group (0.5 mg/kg). Starting on the 22nd day, the drugs were administered by gavage for seven consecutive days. Serum and bronchoalveolar lavage fluid (BALF) were collected. The levels of IL-4 and IgE in the serum and IFN-γ and TNF-α in the BALF were detected by ELISA.
Clinical-Formula Evidence: Clinical studies have shown that formulas containing B. chinensis as the main ingredient have a good therapeutic effect on respiratory diseases. Shegan Mahuang Decoction (SMD), in which B. chinensis is the principal herb, has been used widely for the treatment of asthma in China; however, the clinical effect on asthma had not been well concluded as of that review, which proposed a systematic review and meta-analysis searching seven electronic databases for randomized controlled trials.
Evidence strength: The respiratory indications are well-supported by preclinical (in vitro and animal) data and pharmacopoeial tradition. Clinical evidence comes primarily from studies of multi-herb decoctions rather than B. chinensis in isolation; rigorous, high-quality randomized controlled trials specifically isolating its contribution remain limited.
6.2 Anti-Inflammatory and Analgesic Activity
In vitro and Animal Evidence: In one study, the ethyl acetate extract of B. chinensis (EAEBc) was identified as an excellent source of flavonoids, including irisflorentin, iridin, irigenin, tectorigenin, tectoridin, quercetin, and kaempferol, which could underlie its antinociceptive and anti-inflammatory effects. In rodent models, acetic acid-induced writhing was used for the analgesic test, and the anti-inflammatory activity was tested in carrageenan-induced paw edema. The LDâ‚…â‚€ of tectorigenin was 1.78 g/kg p.o. in mice, and no toxic symptoms were observed at doses up to 300 mg/kg in a subacute toxicity test during 28-day treatment. Tectorigenin at doses of 50 and 100 mg/kg had an analgesic effect on acetic acid-induced acute visceral pain in mice.
Evidence strength: Substantial preclinical (in vitro and rodent) evidence supports anti-inflammatory and analgesic activity. No controlled human clinical trials specifically evaluating Belamcanda for inflammatory conditions were identified.
6.3 Phytoestrogenic / Bone and Hormonal Effects
When tectorigenin was given intravenously to ovariectomized (ovx) rats, it inhibited pulsatile pituitary LH secretion. In postmenopausal women, estrogen-unopposed LH pulses correlate with hot flushes; therefore, suppression of pulsatile LH secretion may be beneficial in women suffering from hot flushes. Upon chronic application to ovariectomized rats, a B. chinensis extract containing 5% Belamcanda at a daily dose of 33 mg or 130 mg of extract had no effect on uterine weight or on estrogen-regulated uterine gene expression, while estrogenic effects in the bone and on bone mineral density of the metaphysis of the tibia could be established. Hence, tectorigenin may have anti-osteoporotic effects in postmenopausal women. Immunohistochemical staining of proliferating cell nuclear antigen — a proliferation marker — in the mammary gland did not indicate a mammotrophic effect of the tectorigenin-containing B. chinensis extract at both tested doses. In summary, tectorigenin or the B. chinensis extract containing tectorigenin had a strong hypothalamotropic and osteotropic effect but no effect in the uterus or the mammary gland.
The estrogenic activity of key isoflavones was tested using Ishikawa cells. Irigenin, tectorigenin, and tectoridin were highly estrogenic (EC₅₀ = 0.75, 0.42, and 0.81 μg/mL, respectively), while iristectorigenin A exhibited weak estrogenic activity (EC₅₀ ≥ 4 μg/mL).
Evidence strength: Estrogenic and SERM-like activities are supported by in vitro and animal model data. The finding of bone-specific estrogenic effects without uterotrophic effects in animal models is notable; no controlled human clinical trials confirming these outcomes in people have been identified.
6.4 Antitumor / Antiproliferative Activity
In recent decades, the pharmacological activities of Belamcandae chinensis rhizoma and isolated compounds have shown anti-tumor, anti-inflammatory, antioxidative, antimutagenic, phytoestrogenic, antidiabetic, antifungal, and antiviral effects.
Prostate Cancer (in vitro/in vivo): Phytoestrogens (50 to 100 μM) and bicalutamide (10 to 50 μM) alone decreased cell number in all three prostate cancer cell lines tested (RWPE-1, LNCaP, PC-3). Phytoestrogens (50 μM) combined with bicalutamide (10 μM) further decreased the number of RWPE-1 and PC-3 cells compared to these agents alone. Tectorigenin and irigenin inhibited the proliferation of RWPE-1, LNCaP, and PC-3 cells, causing G1 arrest and the induction of p21(WAF1) or p27Kip1 protein expression. The animal experiments demonstrated that B. chinensis markedly inhibited the development of tumors in vivo; thus, these compounds may be useful for the prevention or treatment of human prostate cancer.
Breast Cancer (in vitro): All compounds were evaluated for their antiproliferative effects against five tumor cell lines (BT549, 4T1, MCF7, MDA-MB-231, and MDA-MB-468). Among them, compound 9 (an iridal-type triterpenoid) showed the highest activity against 4T1 and MDA-MB-468 cells. Further studies displayed that compound 9 inhibited cell metastasis, induced cell cycle arrest in the G1 phase, and exhibited significant mitochondrial damage in 4T1 and MDA-MB-468 cells, including excess reactive oxygen species.
Broader Anti-cancer Evidence: Potent cytotoxic and antitumor agents effective against various malignancies, including prostate, breast, colon, lung, leukemia, ovarian, and liver cancers, are exhibited by tectoridin and tectorigenin through modulation of multiple signaling pathways involved in migration, apoptosis, cell proliferation, and invasion.
Evidence strength: All current anti-tumor evidence is from in vitro cell-culture studies and animal models. No clinical trials in human cancer patients have been identified. Results are preliminary and require significant further investigation before any clinical conclusions can be drawn.
6.5 Antidiabetic Activity
B. chinensis is a traditional Chinese herbal medicine supported by studies for its remarkable hypoglycemic activity, underscoring its potential in diabetes treatment. Preclinical evidence includes the KK-Ay mouse model of obese diabetes described above (Section 5.5). The extract of Belamcanda chinensis leaves is a traditional Chinese herbal medicine for the treatment of hyperglycemia in Hainan province, South China.
Evidence strength: Antidiabetic activity is supported by in vitro and animal data only. No human clinical trials have been identified in the reviewed sources.
6.6 Hepatoprotective Activity
Hepatoprotective, antihyperglycemic, and anti-alcoholism activities are demonstrated by tectoridin and tectorigenin. Tectoridin has been associated with free-radical scavenging, antioxidant, anti-inflammatory, antiproliferative, oestrogenic, anti-alcohol injury, and hepatoprotective effects in preclinical models.
Evidence strength: Hepatoprotective effects derive from in vitro and animal experiments. Human clinical evidence is absent from the reviewed literature.
6.7 Antibacterial, Antifungal, and Antiviral Activity
Modern pharmacological studies have shown that the extract of Belamcandae Rhizoma also has biological activities such as anti-inflammatory, analgesic, antibacterial, antiviral, antioxidant, anticancer, and estrogen-like effects. Previous pharmacological studies demonstrated that the extract of B. chinensis rhizome has biological effects including antiviral, anti-tumor, antibacterial, and antithrombotic properties.
Evidence strength: Antimicrobial and antiviral activities have been demonstrated in in vitro bioassays. Clinical confirmation in humans is lacking.
6.8 Other Emerging Areas
Modern pharmacological studies indicate that both crude extracts and monomeric compounds exhibit anti-inflammatory, anti-tumor, antioxidant, neuroprotective, and anti-diabetic activities, with potential regulatory pathways. Studies have also demonstrated that B. chinensis exhibits hepatoprotective, antibacterial, and antiviral estrogenic properties, as well as anti-psoriatic and nephroprotective activities.
7. Dosage Forms and Reported Dosages
The 2020 edition of the Chinese Pharmacopoeia recommends a root extract dose of 3–10 g of dried rhizome for decoction-based preparations. This range reflects traditional TCM dosing in combined herbal prescriptions.
In the preclinical (animal) literature, specific doses reported for experimental purposes include:
- Belamcanda chinensis extract administered to guinea pigs at doses of 0.8 g/kg, 1.2 g/kg, and 1.6 g/kg in an asthma model.
- Tectorigenin at doses of 50 and 100 mg/kg administered to mice for analgesic effect in visceral pain models.
- A B. chinensis extract containing 5% tectorigenin administered chronically to ovariectomized rats at a daily dose of 33 mg or 130 mg of extract in a SERM/bone-density study.
- Phytoestrogens (50 to 100 μM) and bicalutamide (10 to 50 μM) were the concentrations used in in vitro prostate cancer cell studies.
No standardized clinical dosage for any indication in humans has been established in the peer-reviewed literature identified. The above dosages from animal studies and in vitro experiments cannot be directly extrapolated to human use.
Belamcandae Rhizoma is the dry rhizome of B. chinensis and has a long history of traditional medicinal use in decocted formulas, powders, and as a component of proprietary TCM preparations. More than 10 proprietary Chinese medicines already on the market consist of or originate from B. chinensis.
8. Safety, Toxicology, and Notable Interactions
8.1 General Toxicological Profile
Modern pharmacological studies have shown that B. chinensis is safe and non-toxic at normal application doses. In most of the herbal writings, it is recorded that Belamcandae Rhizoma has a small toxicity, but so far there are fewer reports on the toxicity of Belamcandae Rhizoma; from the limited studies we can conclude that Belamcandae Rhizoma is safe to use as a medicine at therapeutic doses.
The LDâ‚…â‚€ of tectorigenin was 1.78 g/kg p.o. in mice, and no toxic symptoms were observed at doses up to 300 mg/kg in a subacute toxicity test during 28-day treatment.
8.2 Ichthyotoxicity and Environmental Toxicity
B. chinensis demonstrates toxicity to fish, mollusks, and arthropods. In early research by Japanese scholars, 11 triterpenoids were extracted from Belamcandae Rhizoma and toxicity experiments were carried out with medaka (small fish). As a traditional Chinese medicine with a long history of application, Belamcandae Rhizoma has multifaceted pharmacological activities and is often used in combination with a variety of traditional Chinese medicines as a customary medicine for the treatment of bronchial asthma, tonsillitis, and cough.
8.3 Cytotoxicity of Isolated Compounds
Tectorigenin may exert certain cytotoxicity, which is related to the administration time and concentration. This is a consideration relevant primarily to high-dose or long-duration isolated compound research, not to conventional whole-herb preparations at typical doses.
8.4 Phytoestrogenic Activity: Hormonal Considerations
The most typical traditional usage of Belamcandae chinensis rhizoma is for healing respiratory diseases, but most pharmacological research so far has been focused on isoflavones and their estrogenic properties. Given that tectorigenin binds to both ERα and ERβ receptor subtypes, and in reporter gene transfected cells causes transactivation, populations with hormone-sensitive conditions and those taking exogenous hormonal therapies represent a population in whom the estrogenic effects of B. chinensis constituents warrant particular attention. However, the animal data showing no effect in the uterus or the mammary gland may be reassuring, though this has not been confirmed in human trials.
8.5 Research Gaps in Safety
Currently, there are few studies on the metabolism and toxicology of Belamcandae Rhizoma in humans, and future studies may focus on its in vivo processes, toxicology, and adverse effects. Future clinical studies should also focus on the main therapeutic aspects, toxicity, and adverse effects of B. chinensis.
8.6 Metabolic Interactions
Human liver microsomes (HLMs) and Cytochrome P450 (CYP) recombinant enzymes have been used to study the metabolic stability, identify the metabolic pathways, and determine enzyme kinetics of the major isoflavone aglycones (tectorigenin, irigenin, and irisflorentin) from B. chinensis. Findings from such metabolic profiling studies are relevant to understanding potential drug–herb interactions at the CYP enzyme level, though the precise clinical implications for co-administered pharmaceuticals have not been established in human subjects from the literature reviewed.
9. Systematic Summary of Evidence Strength
- Respiratory (asthma, pharyngitis, cough): Strong traditional and pharmacopoeial backing; substantial in vitro and animal evidence; clinical evidence primarily from multi-herb formulas, not from B. chinensis alone.
- Anti-inflammatory / analgesic: Good preclinical evidence (in vitro, rodent models); no identified human RCTs for the plant per se.
- Phytoestrogenic / SERM / bone: In vitro binding studies and animal SERM-like profiles are notable; no human clinical trial data confirmed.
- Antitumor: Multiple in vitro and some animal data; no clinical trial evidence in humans; all findings are preliminary.
- Antidiabetic: Animal model data only; no human trial data identified.
- Hepatoprotective / antiviral / antibacterial: In vitro and some animal data; no identified human trials.
The knowledge about Belamcandae chinensis rhizoma has been growing rapidly in recent years, but there are still significant gaps in our understanding of its bioactivity, therapeutic value, and roles played by each of the numerous phytochemicals.
References
Go back